PKCθ is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice

Journal of Clinical Investigation

Volumn 119, Issue 12, 2009, Pages 3774-3786

  Valenzuela, Javier O ^a   Iclozan, Cristina ^a   Hossain, Mohammad S ^b   Prlic, Martin ^c   Hopewell, Emily ^a   Bronk, Crystina C ^a   Wang, Junmei ^a   Celis, Esteban ^a,d   Engelman, Robert W ^a,d   Blazar, Bruce R ^e   Bevan, Michael J ^c   Waller, Edmund K ^b   Yu, Xue Zhong ^a,d   Beg, Amer A ^a,d  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MINOR HISTOCOMPATIBILITY ANTIGEN; PROTEIN KINASE C THETA; T LYMPHOCYTE RECEPTOR; ALLOANTIGEN; ISOENZYME; OVA 8; OVA-8; OVALBUMIN; PEPTIDE FRAGMENT; PRKCQ PROTEIN, MOUSE; PROTEIN KINASE C;

ALLOIMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HISTOCOMPATIBILITY; IMMUNE RESPONSE; LEUKEMIA; LISTERIA MONOCYTOGENES; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSPLANTATION; VIRUS INFECTION; ANIMAL; BAGG ALBINO MOUSE; ENZYMOLOGY; EXPERIMENTAL LEUKEMIA; FEMALE; GENETICS; IMMUNOLOGY; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; MALE; MOUSE MUTANT; PHYSIOLOGY; RETROVIRUS INFECTION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; BONE MARROW TRANSPLANTATION; FEMALE; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; ISOANTIGENS; ISOENZYMES; LEUKEMIA, EXPERIMENTAL; LISTERIA MONOCYTOGENES; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, TRANSGENIC; OVALBUMIN; PEPTIDE FRAGMENTS; PROTEIN KINASE C; RETROVIRIDAE INFECTIONS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 72849123229     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI39692     Document Type: Article

References (64)

1. Greenwald, R.J., Freeman, G.J., and Sharpe, A.H. 2005. The B7 family revisited. Annu. Rev. Immunol. 23:515-548.
2. Watts, T.H. 2005. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23:23-68. (Pubitemid 40563164)
3. Curtsinger, J.M., Gerner, M.Y., Lins, D.C., and Mescher, M.F. 2007. Signal 3 availability limits the CD8 T cell response to a solid tumor. J. Immunol. 178:6752-6760.
4. Samelson, L.E. 2002. Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins. Annu. Rev. Immunol. 20:371-394. (Pubitemid 34293429)
5. Spitaler, M., and Cantrell, D.A. 2004. Protein kinase C and beyond. Nat. Immunol. 5:785-790.
6. Isakov, N., and Altman, A. 2002. Protein kinase C(theta) in T cell activation. Annu. Rev. Immunol. 20:761-794. (Pubitemid 34293439)
7. Sun, Z., et al. 2000. PKC-theta is required for TCRinduced NF-kappaB activation in mature but not immature T lymphocytes. Nature. 404:402-407.
8. Pfeifhofer, C., et al. 2003. Protein kinase C theta affects Ca2+ mobilization and NFAT cell activation in primary mouse T cells. J. Exp. Med. 197:1525-1535.
9. Grumont, R., et al. 2004. The mitogen-induced increase in T cell size involves PKC and NFAT activation of Rel/NF-kappaB-dependent c-myc expression. Immunity. 21:19-30. (Pubitemid 38925264)
10. Barouch-Bentov, R., et al. 2005. Protein kinase C-theta is an early survival factor required for differentiation of effector CD8+ T cells. J. Immunol. 175:5126-5134.
11. Berg-Brown, N.N., et al. 2004. PKCtheta signals activation versus tolerance in vivo. J. Exp. Med. 199:743-752.
12. Marsland, B.J., et al. 2007. TLR ligands act directly upon T cells to restore proliferation in the absence of protein kinase C-theta signaling and promote autoimmune myocarditis. J. Immunol. 178:3466-3473.
13. Salek-Ardakani, S., So, T., Halteman, B.S., Altman, A., and Croft, M. 2005. Protein kinase Ctheta controls Th1 cells in experimental autoimmune encephalomyelitis. J. Immunol. 175:7635-7641. (Pubitemid 41713463)
14. Healy, A.M., et al. 2006. PKC-theta-deficient mice are protected from Th1-dependent antigeninduced arthritis. J. Immunol. 177:1886-1893.
15. Marsland, B.J., Soos, T.J., Spath, G., Littman, D.R., and Kopf, M. 2004. Protein kinase C theta is critical for the development of in vivo T helper (Th)2 cell but not Th1 cell responses. J. Exp. Med. 200:181-189. (Pubitemid 38982177)
16. Marsland, B.J., et al. 2005. Innate signals compensate for the absence of PKC-{theta} during in vivo CD8(+) T cell effector and memory responses. Proc. Natl. Acad. Sci. U. S. A. 102:14374-14379.
17. Shlomchik, W.D. 2007. Graft-versus-host disease. Nat. Rev. Immunol. 7:340-352.
18. Ferrara, J.L., Levy, R., and Chao, N.J. 1999. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol. Blood Marrow Transplant. 5:347-356.
19. Welniak, L.A., Blazar, B.R., and Murphy, W.J. 2007. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu. Rev. Immunol. 25:139-170. (Pubitemid 46697905)
20. Marty, F.M., and Rubin, R.H. 2006. The persistent challenges of bacterial infections in the transplant recipient. Transpl. Infect. Dis. 8:125-127. (Pubitemid 44196178)
21. Rubin, R.H., and Marty, F.M. 2004. Principles of antimicrobial therapy in the transplant patient. Transpl. Infect. Dis. 6:97-100.
22. Reddy, P., et al. 2005. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus- leukemia responses. Nat. Med. 11:1244-1249. (Pubitemid 43093673)
23. Harty, J.T., Schreiber, R.D., and Bevan, M.J. 1992. CD8 T cells can protect against an intracellular bacterium in an interferon gamma-independent fashion. Proc. Natl. Acad. Sci. U. S. A. 89:11612-11616.
24. Sakowicz-Burkiewicz, M., et al. 2008. Protein kinase C-theta critically regulates the proliferation and survival of pathogen-specific T cells in murine listeriosis. J. Immunol. 180:5601-5612.
25. Zheng, Y., Vig, M., Lyons, J., Van Parijs, L., and Beg, A.A. 2003. Combined deficiency of p50 and cRel in CD4+ T cells reveals an essential requirement for NF-kB in regulating mature T cell survival and in vivo function. J. Exp. Med. 197:861-874. (Pubitemid 36437863)
26. Marsland, B.J., and Kopf, M. 2008. T-cell fate and function: PKC-theta and beyond. Trends Immunol. 29:179-185.
27. Yu, X.Z., et al. 2006. Opposing effects of ICOS on graft-versus-host disease mediated by CD4 and CD8 T cells. J. Immunol. 176:7394-7401.
28. Liang, Y., et al. 2007. {beta}2 integrins separates graft-versus-host disease and graft-versus-leukemia effect. Blood. 111:954-962.
29. Blazar, B.R., Korngold, R., and Vallera, D.A. 1997. Recent advances in graft-versus-host disease (GVHD) prevention. Immunol. Rev. 157:79-109. (Pubitemid 27303123)
30. Manicassamy, S., et al. 2008. A critical role for protein kinase C-theta-mediated T cell survival in cardiac allograft rejection. J. Immunol. 181:513-520.
31. Yu, X.Z., Albert, M.H., and Anasetti, C. 2006. Alloantigen affinity and CD4 help determine severity of graft-versus-host disease mediated by CD8 donor T cells. J. Immunol. 176:3383-3390. (Pubitemid 43363985)
32. Yu, X.Z., Bidwell, S.J., Martin, P.J., and Anasetti, C. 2000. CD28-specific antibody prevents graft-versushost disease in mice. J. Immunol. 164:4564-4568. (Pubitemid 30238053)
33. Sha, W.C., et al. 1988. Positive and negative selection of an antigen receptor on T cells in transgenic mice. Nature. 336:73-76. (Pubitemid 18262137)
34. Sha, W.C., et al. 1988. Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice. Nature. 335:271-274. (Pubitemid 18224875)
35. Corr, M., et al. 1994. T cell receptor-MHC class I peptide interactions: affinity, kinetics, and specificity. Science. 265:946-949.
36. Cai, Z., and Sprent, J. 1996. Influence of antigen dose and costimulation on the primary response of CD8+ T cells in vitro. J. Exp. Med. 183:2247-2257. (Pubitemid 26158916)
37. Hogquist, K.A., et al. 1994. T cell receptor antagonist peptides induce positive selection. Cell. 76:17-27. (Pubitemid 24035278)
38. Yachi, P.P., Ampudia, J., Zal, T., and Gascoigne, N.R. 2006. Altered peptide ligands induce delayed CD8- T cell receptor interaction - a role for CD8 in distinguishing antigen quality. Immunity. 25:203-211. (Pubitemid 44224141)
39. Yu, X.Z., Bidwell, S., Martin, P.J., and Anasetti, C. 1999. Visualization, fate, and pathogenicity of antigen- specific CD8+ T cells in the graft-versus-host reaction. J. Immunol. 163:4780-4787. (Pubitemid 29501240)
40. Ahonen, C.L., et al. 2004. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J. Exp. Med. 199:775-784.
41. Ahonen, C.L., et al. 2008. Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood. 111:3116-3125.
42. Assudani, D., Cho, H.I., DeVito, N., Bradley, N., and Celis, E. 2008. In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells. Cancer Res. 68:9892-9899.
43. Taylor, P.A., et al. 2008. TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. Blood. 112:3508-3516.
44. Hossain, M.S., et al. 2007. Chronic GvHD decreases antiviral immune responses in allogeneic BMT. Blood. 109:4548-4556.
45. Hossain, M.S., Roback, J.D., Wang, F., and Waller, E.K. 2008. Host and donor immune responses contribute to antiviral effects of amotosalen-treated donor lymphocytes following early posttransplant cytomegalovirus infection. J. Immunol. 180:6892-6902.
46. Meyers, J.D., Flournoy, N., and Thomas, E.D. 1986. Risk factors for cytomegalovirus infection after human marrow transplantation. J. Infect. Dis. 153:478-488. (Pubitemid 16135651)
47. Cohen, J.L., Trenado, A., Vasey, D., Klatzmann, D., and Salomon, B.L. 2002. CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus- host disease. J. Exp. Med. 196:401-406. (Pubitemid 34875668)
48. Gupta, S., et al. 2008. Differential requirement of PKC-theta in the development and function of natural regulatory T cells. Mol. Immunol. 46:213-224.
49. Waldman, E., et al. 2006. Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. Blood. 107:1703-1711.
50. Petrovic, A., et al. 2004. LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graftversus- host disease. Blood. 103:1542-1547.
51. Choi, S.W., et al. 2007. CCR1/CCL5 (RANTES) receptor- ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation. Blood. 110:3447-3455.
52. Varona, R., Cadenas, V., Gomez, L., Martinez, A.C., and Marquez, G. 2005. CCR6 regulates CD4+ T-cell-mediated acute graft-versus-host disease responses. Blood. 106:18-26. (Pubitemid 40967169)
53. Terwey, T.H., et al. 2005. CCR2 is required for CD8-induced graft-versus-host disease. Blood. 106:3322-3330.
54. Wagner, J.E., et al. 2002. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 100:1611-1618.
55. Barker, J.N., et al. 2005. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood. 105:1343-1347.
56. MacMillan, M.L., et al. 2009. Acute graft-versushost disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood. 113:2410-2415.
57. Grybko, M.J., Pores-Fernando, A.T., Wurth, G.A., and Zweifach, A. 2007. Protein kinase C activity is required for cytotoxic T cell lytic granule exocytosis, but the theta isoform does not play a preferential role. J. Leukoc. Biol. 81:509-519. (Pubitemid 46198403)
58. Manicassamy, S., and Sun, Z. 2007. The critical role of protein kinase C-theta in Fas/Fas ligand-mediated apoptosis. J. Immunol. 178:312-319. (Pubitemid 46033614)
59. Schmaltz, C., et al. 2001. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versusleukemia effect. Blood. 97:2886-2895.
60. Schmaltz, C., et al. 2002. T cells require TRAIL for optimal graft-versus-tumor activity. Nat. Med. 8:1433-1437.
61. Letschka, T., et al. 2008. PKC-theta selectively controls the adhesion-stimulating molecule Rap1. Blood. 112:4617-4627.
62. Fischbein, M.P., et al. 2000. CD40 signaling replaces CD4+ lymphocytes and its blocking prevents chronic rejection of heart transplants. J. Immunol. 165:7316-7322.
63. Mueller, S.N., Jones, C.M., Smith, C.M., Heath, W.R., and Carbone, F.R. 2002. Rapid cytotoxic T lymphocyte activation occurs in the draining lymph nodes after cutaneous herpes simplex virus infection as a result of early antigen presentation and not the presence of virus. J. Exp. Med. 195:651-656.
64. Wang, X., et al. 2007. Lack of essential role of NF-kappa B p50, RelA, and cRel subunits in virus-induced type 1 IFN expression. J. Immunol. 178:6770-6776. (Pubitemid 46847401)